Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early responseFara Brasó‐Maristany, Mafalda Oliveira, J.M. Ferrero-Cafiero et al.|Nature Communications|2024Cited by 23
HER2 and HER3 expression during neoadjuvant treatment of HER2‐negative early breast cancer: potential for biomarker‐driven sequencing of T‐DXd and HER3‐DXdChristian F. Singer, Ulrike Heber, Charlotte Mang‐Manger et al.|癌症：英文版|2025Cited by 3